1. Diagnosis dan rawatan pertama kanser paru-paru
Pesakit Lu telah didiagnosis dengan adenokarsinoma paru-paru dan metastasis nodus limfa pada 26 Ogos 2005. Lobektomi bawah kiri dilakukan pada 22 September 2005. Carboplatin digabungkan dengan taxotere digunakan 4 kali selepas pembedahan. Pada 3 Ogos 2007, disebabkan efusi pleura, diagnosis disahkan berulang, dan dia dirawat dengan Tarceva (bilangan kitaran tidak diketahui). Pada 8 Januari 2008, perkembangan kanser didapati pada pemeriksaan semula, dan kemudian rawatan Tarceva dihentikan dan rawatan Libita dimulakan selama 16 kitaran. Pada masa yang sama, metastasis pinggul vertebra ditemui dan 4 kitaran Zetai telah dilakukan.
2. Kali pertama mengambil bahagian dalam ujian klinikal, keadaan adalah terkawal.
In July 2010, Mr. Lu reexamined a large area of brain metastasis and found dozens of small lesions in the brain. He also tested positive for the EML4-ALK fusion gene at the University of Chicago School of Medicine. The whole brain radiation therapy was then used to control the lesions, and the second phase of crizotinib drug trial was started at St. Louis University Hospital. During the treatment, the condition was stably controlled, but a re-examination in May 2012 found that the cancer had progressed slightly, and the tumor was suspected to be resistant to crizotinib. He stopped crizotinib on July 18, 2012.
3. Dalam percubaan klinikal kedua, tumor hilang dengan jelas.
On August 6, 2012, Mr. Lu participated in the AP26113 drug percubaan klinikal at Denver Hospital. In October, the PET examination showed that the tumor disappeared and the tumor dalam otak decreased and became large.
4. Temui mutasi gen yang jarang berlaku dan berharap untuk mengambil bahagian dalam ujian klinikal baharu
Pemeriksaan semula pada Julai 2014, PET seluruh badan menunjukkan: Lesi otak pada asasnya stabil, dan dada menunjukkan kemajuan yang jelas. Pada 12 Mei 2014, saluran sel kultur anti-AP26113 yang disyaki (3 sel, terbesar 1.1 cm) telah dilakukan di Hospital Besar Massachusetts dan terus mengambil AP26113.
In August 2014, the doctor called and found that Mr. Lu’s new tumor tissue sequencing detected rare or unseen mutations. This mutation was only reported in ALK-positive children’s neuroblastoma and inflammatory myofibroblastoma. Previous research reports and medical evidence have shown that crizotinib cannot cope with the resistant neuroblastoma caused by this mutation. New genetic test results indicate that Mr. Lu may need to find new drugs for treatment.
On December 8, 2014, after a doctor’s analysis and decision, Mr. Lu was approved to increase the dosage of AP26113 and changed it to 240 mg per day, so the drug replacement plan was temporarily delayed. After observing the efficacy, he decided whether to change the drug and participate in other clinical trials. The patient learned through the hospital that NIVOLUMAB monoclonal antibody imunoterapi phase 3/4 drug test is recruiting lung cancer patients on a large scale, and Mr. Lu is fully confident of the future anti-cancer.
